<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00404352</url>
  </required_header>
  <id_info>
    <org_study_id>IMP27025</org_study_id>
    <secondary_id>2006-002982-38</secondary_id>
    <nct_id>NCT00404352</nct_id>
  </id_info>
  <brief_title>REbif FLEXible Dosing in Early Multiple Sclerosis (MS)</brief_title>
  <acronym>REFLEX</acronym>
  <official_title>A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial of Rebif New Formulation (44 Microgram [Mcg] Three Times Weekly [Tiw] and 44 Mcg Once Weekly [ow]) in Subjects at High Risk of Converting to Multiple Sclerosis (REFLEX)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck KGaA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a 24 months randomized, double-blind, Placebo-controlled, multi-center clinical
      trial with an optional 12 months open label extension.

      The primary objective of the study is to evaluate the effect of fetal bovine serum
      [FBS]-free/human serum albumin [HSA]-free formulation of Interferon [IFN] beta-1a (RNF) 44
      microgram (three times weekly and once weekly) versus placebo on the time to conversion to
      McDonald multiple sclerosis (MS) criteria (2005) in subjects with a first clinical
      demyelinating event at high risk of converting to MS.

      The main secondary objective of study is to evaluate the effect of RNF 44 microgram (three
      times weekly and once weekly) versus placebo on the &quot;Time to conversion to clinically
      definite MS (CDMS)&quot; in subjects with a first clinical demyelinating event at high risk of
      converting to MS.

      At the end of 24 month double-blind core REFLEX trial, subjects who will not convert to CDMS
      and decide to receive open-label (OL) treatment will be enrolled into an open-label, 12 month
      extension period to evaluate the effect of RNF 44 mcg three times weekly treatment on the
      time to conversion to McDonald MS and time to conversion to CDMS.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Conversion to Multiple Sclerosis (MS) According to the McDonald Criteria (2005)</measure>
    <time_frame>Various time points from randomization up to 24 months</time_frame>
    <description>The McDonald criteria use dissemination in time and space established by magnetic resonance image (MRI) findings to provide a clinical diagnosis for MS. Dissemination in time is established by a new time constant 2 (T2) or gadolinium-enhancing (Gd+) lesion found on a repeat MRI. Dissemination in space is established by the presence of any 3 of the following: 1 Gd+ lesion or 9 T2 bright lesions if there is no enhancement; greater than or equal to 1 infratentorial lesion; greater than or equal to 1 juxtacortical lesion; greater than or equal to 3 periventricular lesions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Conversion to Multiple Sclerosis (MS) According to the McDonald Criteria (2005)</measure>
    <time_frame>Various time points from randomization up to 36 months</time_frame>
    <description>The McDonald criteria use dissemination in time and space established by MRI findings to provide a clinical diagnosis for MS. Dissemination in time is established by a T2 or Gd+ lesion found on a repeat MRI. Dissemination in space is established by the presence of any 3 of the following: 1 Gd+ lesion or 9 T2 bright lesions if there is no enhancement; greater than or equal to 1 infratentorial lesion; greater than or equal to 1 juxtacortical lesion; greater than or equal to 3 periventricular lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) Defined by Either a Second Attack or a 3-Month Sustained Increase (Greater Than or Equal to 1.5 Points) in the Expanded Disability Status Scale (EDSS) Score</measure>
    <time_frame>Various time points from randomization up to 24 months</time_frame>
    <description>CDMS was defined by the occurrence of a second exacerbation or relapse over 24 months in participants who presented with first clinical demyelinating event (FCDE) accompanied by an abnormal MRI scan. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) Defined by Either a Second Attack or a 3-Month Sustained Increase (Greater Than or Equal to 1.5 Points) in the Expanded Disability Status Scale (EDSS) Score</measure>
    <time_frame>Various time points from randomization up to 36 months</time_frame>
    <description>CDMS was defined by the occurrence of a second exacerbation or relapse over 36 months in participants who presented with FCDE accompanied by an abnormal MRI scan. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Combined Unique Active (CUA) Lesions, New Time Constant 2 (T2) Lesions, Gadolinium Enhanced (Gd+) Lesions and New Time Constant 1 (T1) Hypointense Lesions Per Participant Per Scan</measure>
    <time_frame>Month 24 up to Month 36</time_frame>
    <description>Number of CUA lesions, new T2 lesions, Gd+ lesions and new T1 hypointense lesions were measured by using MRI scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Time Constant 2 (T2) Lesion Volume , Time Constant 1 (T1) Hypointense Lesion Volume and Gadolinium Enhanced (Gd+) Lesion Volume at Month 36</measure>
    <time_frame>Baseline, Month 36</time_frame>
    <description>Change from baseline in lesion volume was measured by using MRI scans for T2 lesions, T1 hypointense lesions and (Gd+) lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Expanded Disability Status Score (EDSS) Score at Month 36</measure>
    <time_frame>Baseline, Month 36</time_frame>
    <description>EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. The change in EDSS at Month 36 was calculated as EDSS at Month 36 minus EDSS at baseline.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">517</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>RNF 44 mcg three times weekly</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>RNF 44 mcg once weekly and placebo twice weekly for blinding</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo three times weekly</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RNF</intervention_name>
    <description>Single dose of RNF administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 microgram (mcg) for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months, or 36 months for patients enrolled in the OL extension.</description>
    <arm_group_label>RNF 44 mcg three times weekly</arm_group_label>
    <arm_group_label>RNF 44 mcg once weekly and placebo twice weekly for blinding</arm_group_label>
    <other_name>Rebif</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RNF</intervention_name>
    <description>Single dose of RNF administered subcutaneously once weekly at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months.</description>
    <arm_group_label>RNF 44 mcg three times weekly</arm_group_label>
    <arm_group_label>RNF 44 mcg once weekly and placebo twice weekly for blinding</arm_group_label>
    <other_name>Rebif</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo was supplied as a transparent, sterile solution for injection in pre-filled syringes matching the RNF pre-filled syringes, each containing 0.5 mL.</description>
    <arm_group_label>RNF 44 mcg once weekly and placebo twice weekly for blinding</arm_group_label>
    <arm_group_label>Placebo three times weekly</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Single, first clinical event suggestive of MS within 60 days prior to study Day 1,
             which is the day of randomization (clock starts 24 hours after onset). The event must
             be a new neurological abnormality present for at least 24 hours, either mono- or
             polysymptomatic, other than a paresthesia, vegetative or cerebral dysfunction

          -  At least two clinically silent lesions on the T2-weighted MRI scan, with a size of at
             least 3 millimeter (mm), at least one of which is ovoid or periventricular or
             infratentorial

          -  EDSS 0 - 5.0 at least one time point during the screening period before start of
             treatment

          -  18 and 50 years old, inclusive

          -  Willing to follow study procedures

          -  Written informed consent

          -  If female, subject must:

               -  be neither pregnant nor breast-feeding nor attempting to conceive

               -  use a highly effective method of contraception. A highly effective method of
                  contraception is defined as those which result in a low failure rate (that is
                  [i.e.] less than 1 percent [%] per year) when used consistently and correctly
                  such as implants, injectables, combined oral contraceptives, some intrauterine
                  devices (IUDs), sexual abstinence or vasectomised partner

        Exclusion Criteria:

          -  Diagnosis of MS (per McDonald criteria 2005)

          -  Any other disease that could better explain the subject's signs and symptoms

          -  Complete transverse myelitis or bilateral optic neuritis

          -  Subject uses or has used any other approved MS disease-modifying drug (DMD)

          -  Any investigational drug or undergone an experimental procedure within 12 weeks prior
             to study Day 1

          -  Oral or systemic corticosteroids or adrenocorticotropic hormone (ACTH) within 30 days
             prior to study Day 1

          -  Total bilirubin greater than 2.5 times upper limit of normal (ULN)

          -  Subject has total aspartate aminotransferase (AST) or alanine aminotransferase (ALT)
             or alkaline phosphatase (ALP) greater than 2.5 times the ULN

          -  Inadequate bone marrow reserve, defined as a total white blood cell count less than
             3.0 x 109 per liter (/L), platelet count less than 75 x 109/L, hemoglobin less than
             100 gram per liter (g/L)

          -  Current autoimmune disease

          -  Major medical or psychiatric illness (including history of or current severe
             depressive disorders and/or suicidal ideation) that in the opinion of the investigator
             creates undue risk to the subject or could affect compliance with the study protocol

          -  History of seizures not adequately controlled by treatment

          -  Cardiac disease, such as angina, congestive heart failure or arrhythmia

          -  Known allergy to IFN-beta or the excipient(s) of the study medication

          -  Any condition that could interfere with the MRI evaluation;

          -  Known allergy to gadolinium-diethylene triamine pentaacetic acid (DTPA)

          -  Previously participated in this study

          -  Participated in any clinical trial within the past 6 months

          -  Any immunomodulatory or immunosuppressive therapy at any time prior to enrollment,
             including, but not limited to, the following products: any IFN, glatiramer acetate
             (Copolymer I), cyclophosphamide, cyclosporine, methotrexate, linomide, azathioprine,
             mitoxantrone, teriflunomide, laquinimod, cladribine, total lymphoid irradiation,
             anti-lymphocyte monoclonal antibody treatment (e.g. natalizumab, alemtuzumab/Campath,
             anti-cluster of differentiation 4 [CD4]), intravenous, immunoglobulins (Igs),
             cytokines or anti-cytokine therapy

          -  Any experimental MS treatment prior to trial entry, including, but not limited to, any
             statins (if given to prevent MS) and pentoxyfylline

          -  History of alcohol or drug abuse

          -  Intolerance or any contraindication to both paracetamol (acetaminophen) and ibuprofen

          -  Inability to administer subcutaneous injections either by self or by caregiver

          -  Moderate to severe renal impairment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bettina M. Stubinski, MD</last_name>
    <role>Study Director</role>
    <affiliation>Merck Serono S.A., Geneva</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mendoza</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>B-Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brugge</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rousse</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shumen</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal, Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ontario</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Victoria British Columbia</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Karlovac</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osijek</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rijeka</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Split</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hradec Kralove</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Olomouc</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>OYS</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vantaa</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poissy Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Henningsdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ness Ziona</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Safed</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tel-Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rabat</city>
        <country>Morocco</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Targu-Mures</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nizhny Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nis</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Presov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bilbao</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Lebanon</country>
    <country>Morocco</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Saudi Arabia</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Turkey</country>
  </location_countries>
  <removed_countries>
    <country>Denmark</country>
    <country>Switzerland</country>
  </removed_countries>
  <link>
    <url>http://www.mslifelines.com</url>
    <description>Full FDA approved prescribing information can be found here</description>
  </link>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2006</study_first_submitted>
  <study_first_submitted_qc>November 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2006</study_first_posted>
  <results_first_submitted>May 15, 2012</results_first_submitted>
  <results_first_submitted_qc>August 23, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 24, 2012</results_first_posted>
  <last_update_submitted>December 18, 2013</last_update_submitted>
  <last_update_submitted_qc>December 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rebif New Formulation</keyword>
  <keyword>Clinical Isolated Syndrome</keyword>
  <keyword>Multiple Sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferon beta-1a</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The participants were recruited in 78 centers across 28 countries for REFLEX study. REFLEX 12 months open label extension (OLE) was conducted at 11 active centers in 9 countries.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>RNF 44 Mcg Three Times Weekly (Double Blind [DB] Population)</title>
          <description>Single dose of fetal bovine serum [FBS]-free/human serum albumin [HSA]-free formulation of interferon [IFN]-beta-1a (RNF) injection administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 microgram (mcg) for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months or until conversion to clinically definite multiple sclerosis (CDMS) whichever occurs first.</description>
        </group>
        <group group_id="P2">
          <title>RNF 44 Mcg Once Weekly (DB Population)</title>
          <description>Single dose of RNF injection administered subcutaneously once weekly plus 2 matching placebo doses at least 48 hours apart at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months or until conversion to CDMS whichever occurs first.</description>
        </group>
        <group group_id="P3">
          <title>Placebo (DB Population)</title>
          <description>Single dose of matching placebo administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months or until conversion to CDMS whichever occurs first.</description>
        </group>
        <group group_id="P4">
          <title>RNF 44 Mcg Three Times Weekly/OL RNF 44 Mcg Three Times Weekly</title>
          <description>After having converted to CDMS, participants received open-label (OL) study treatment with RNF. Single dose of RNF injection administrated subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months.</description>
        </group>
        <group group_id="P5">
          <title>RNF 44 Mcg Once Weekly/OL RNF 44 Mcg Three Times Weekly</title>
          <description>After having converted to CDMS, participants received OL study treatment with RNF. Single dose of RNF injection administrated subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months.</description>
        </group>
        <group group_id="P6">
          <title>Placebo/OL RNF 44 Mcg Three Times Weekly</title>
          <description>After having converted to CDMS, participants received OL study treatment with RNF. Single dose of RNF injection administrated subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months.</description>
        </group>
        <group group_id="P7">
          <title>RNF 44Mcg Three Times Weekly/RNF 44Mcg Three Times Weekly(OLE)</title>
          <description>Participants who were not converted to CDMS and completed 24 month core REFLEX trial were enrolled in a 1 year open label extension (OLE). Participants who had received RNF three times a week in the core REFLEX trial, were re-titrated with a single dose of RNF injection administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 36 months in this 12 months open label extension.</description>
        </group>
        <group group_id="P8">
          <title>RNF 44 Mcg Once Weekly/RNF 44 Mcg Three Times Weekly (OLE)</title>
          <description>Participants who were not converted to CDMS and completed 24 month core REFLEX trial were enrolled in a 1 year OLE. Participants who had received RNF once weekly in the core REFLEX trial were re-titrated with a single dose of RNF injection subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 36 months in this 12 months open label extension.</description>
        </group>
        <group group_id="P9">
          <title>Placebo/RNF 44 Mcg Three Times Weekly (OLE)</title>
          <description>Participants who were not converted to CDMS and completed 24 month core REFLEX trial were enrolled in a 1 year OLE. Participants who had received placebo in the core REFLEX trial were re-titrated with a single dose of RNF injection subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 36 months in this 12 months open label extension.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double Blind (up to 24 Month)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="171"/>
                <participants group_id="P2" count="175"/>
                <participants group_id="P3" count="171"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="171"/>
                <participants group_id="P2" count="173"/>
                <participants group_id="P3" count="171"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="119"/>
                <participants group_id="P2" count="128"/>
                <participants group_id="P3" count="92"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="79"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Switched to open label phase</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="59"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but not treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open Label (up to 24 Month)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="31">From DB period, 31 participants converted to CDMS and switched to OL period in this study</participants>
                <participants group_id="P5" count="30">From DB period, 30 participants converted to CDMS and switched to OL period in this study</participants>
                <participants group_id="P6" count="59">From DB period, 59 participants converted to CDMS and switched to OL period in this study</participants>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="28"/>
                <participants group_id="P5" count="28"/>
                <participants group_id="P6" count="52"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open Label Extension (up to 36 Months)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="4">4 participants who did not convert to CDMS in 24 months and gave consent to enroll in OLE period</participants>
                <participants group_id="P8" count="5">5 participants who did not convert to CDMS in 24 months and gave consent to enroll in OLE period</participants>
                <participants group_id="P9" count="11">11 participants who did not convert to CDMS in 24 months and gave consent to enroll in OLE period</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RNF 44 Mcg Three Times Weekly (Double Blind [DB] Population)</title>
          <description>Single dose of fetal bovine serum [FBS]-free/human serum albumin [HSA]-free formulation of interferon [IFN]-beta-1a (RNF) injection administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 microgram (mcg) for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months or until conversion to clinically definite multiple sclerosis (CDMS) whichever occurs first.</description>
        </group>
        <group group_id="B2">
          <title>RNF 44 Mcg Once Weekly (DB Population)</title>
          <description>Single dose of RNF injection administered subcutaneously once weekly plus 2 matching placebo doses at least 48 hours apart at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months or until conversion to CDMS whichever occurs first.</description>
        </group>
        <group group_id="B3">
          <title>Placebo (DB Population)</title>
          <description>Single dose of matching placebo administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months or until conversion to CDMS whichever occurs first.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="171"/>
            <count group_id="B2" value="175"/>
            <count group_id="B3" value="171"/>
            <count group_id="B4" value="517"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.6" spread="8.5"/>
                    <measurement group_id="B2" value="30.7" spread="8.1"/>
                    <measurement group_id="B3" value="30.9" spread="7.9"/>
                    <measurement group_id="B4" value="30.7" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Less than 30 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="87"/>
                    <measurement group_id="B4" value="259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greater than or equal to 30 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="84"/>
                    <measurement group_id="B4" value="258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="112"/>
                    <measurement group_id="B4" value="332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="59"/>
                    <measurement group_id="B4" value="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171"/>
                    <measurement group_id="B2" value="174"/>
                    <measurement group_id="B3" value="171"/>
                    <measurement group_id="B4" value="516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Conversion to Multiple Sclerosis (MS) According to the McDonald Criteria (2005)</title>
        <description>The McDonald criteria use dissemination in time and space established by magnetic resonance image (MRI) findings to provide a clinical diagnosis for MS. Dissemination in time is established by a new time constant 2 (T2) or gadolinium-enhancing (Gd+) lesion found on a repeat MRI. Dissemination in space is established by the presence of any 3 of the following: 1 Gd+ lesion or 9 T2 bright lesions if there is no enhancement; greater than or equal to 1 infratentorial lesion; greater than or equal to 1 juxtacortical lesion; greater than or equal to 3 periventricular lesions.</description>
        <time_frame>Various time points from randomization up to 24 months</time_frame>
        <population>Intent-to-treat (ITT) population included all participants who were randomized to the assigned study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>RNF 44 Mcg Three Times Weekly (Double Blind [DB] Population)</title>
            <description>Single dose of fetal bovine serum [FBS]-free/human serum albumin [HSA]-free formulation of interferon [IFN]-beta-1a (RNF) injection administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 microgram (mcg) for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months or until conversion to clinically definite multiple sclerosis (CDMS) whichever occurs first.</description>
          </group>
          <group group_id="O2">
            <title>RNF 44 Mcg Once Weekly (DB Population)</title>
            <description>Single dose of RNF injection administered subcutaneously once weekly plus 2 matching placebo doses at least 48 hours apart at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months or until conversion to CDMS whichever occurs first.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (DB Population)</title>
            <description>Single dose of matching placebo administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months or until conversion to CDMS whichever occurs first.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Conversion to Multiple Sclerosis (MS) According to the McDonald Criteria (2005)</title>
          <description>The McDonald criteria use dissemination in time and space established by magnetic resonance image (MRI) findings to provide a clinical diagnosis for MS. Dissemination in time is established by a new time constant 2 (T2) or gadolinium-enhancing (Gd+) lesion found on a repeat MRI. Dissemination in space is established by the presence of any 3 of the following: 1 Gd+ lesion or 9 T2 bright lesions if there is no enhancement; greater than or equal to 1 infratentorial lesion; greater than or equal to 1 juxtacortical lesion; greater than or equal to 3 periventricular lesions.</description>
          <population>Intent-to-treat (ITT) population included all participants who were randomized to the assigned study treatment.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
                <count group_id="O2" value="175"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="310" lower_limit="183" upper_limit="488"/>
                    <measurement group_id="O2" value="182" lower_limit="107" upper_limit="270"/>
                    <measurement group_id="O3" value="97" lower_limit="93" upper_limit="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Log Rank</method>
            <method_desc>Log-rank test was stratified for controlling randomization stratification factors.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Log Rank</method>
            <method_desc>Log-rank test was stratified for controlling randomization stratification factors.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>Log Rank</method>
            <method_desc>Log-rank test was stratified for controlling randomization stratification factors.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) Defined by Either a Second Attack or a 3-Month Sustained Increase (Greater Than or Equal to 1.5 Points) in the Expanded Disability Status Scale (EDSS) Score</title>
        <description>CDMS was defined by the occurrence of a second exacerbation or relapse over 24 months in participants who presented with first clinical demyelinating event (FCDE) accompanied by an abnormal MRI scan. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated.</description>
        <time_frame>Various time points from randomization up to 24 months</time_frame>
        <population>ITT population included all participants who were randomized to the assigned study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>RNF 44 Mcg Three Times Weekly (Double Blind [DB] Population)</title>
            <description>Single dose of fetal bovine serum [FBS]-free/human serum albumin [HSA]-free formulation of interferon [IFN]-beta-1a (RNF) injection administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 microgram (mcg) for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months or until conversion to clinically definite multiple sclerosis (CDMS) whichever occurs first.</description>
          </group>
          <group group_id="O2">
            <title>RNF 44 Mcg Once Weekly (DB Population)</title>
            <description>Single dose of RNF injection administered subcutaneously once weekly plus 2 matching placebo doses at least 48 hours apart at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months or until conversion to CDMS whichever occurs first.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (DB Population)</title>
            <description>Single dose of matching placebo administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months or until conversion to CDMS whichever occurs first.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) Defined by Either a Second Attack or a 3-Month Sustained Increase (Greater Than or Equal to 1.5 Points) in the Expanded Disability Status Scale (EDSS) Score</title>
          <description>CDMS was defined by the occurrence of a second exacerbation or relapse over 24 months in participants who presented with first clinical demyelinating event (FCDE) accompanied by an abnormal MRI scan. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated.</description>
          <population>ITT population included all participants who were randomized to the assigned study treatment.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
                <count group_id="O2" value="175"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Non-estimable: Insufficient participants reached the median percentile to calculate the upper and lower limits of confidence interval.</measurement>
                    <measurement group_id="O2" value="NA">Non-estimable: Insufficient participants reached the median percentile to calculate the upper and lower limits of confidence interval.</measurement>
                    <measurement group_id="O3" value="NA">Non-estimable: Insufficient participants reached the median percentile to calculate the upper and lower limits of confidence interval.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Log Rank</method>
            <method_desc>Log-rank test was stratified for controlling randomization stratification factors.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Log Rank</method>
            <method_desc>Log-rank test was stratified for controlling randomization stratification factors.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.774</p_value>
            <method>Log Rank</method>
            <method_desc>Log-rank test was stratified for controlling randomization stratification factors.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) Defined by Either a Second Attack or a 3-Month Sustained Increase (Greater Than or Equal to 1.5 Points) in the Expanded Disability Status Scale (EDSS) Score</title>
        <description>CDMS was defined by the occurrence of a second exacerbation or relapse over 36 months in participants who presented with FCDE accompanied by an abnormal MRI scan. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated.</description>
        <time_frame>Various time points from randomization up to 36 months</time_frame>
        <population>OL ITT population included all participants who were randomized at baseline in core REFLEX trial and entered the 12 months OLE period.</population>
        <group_list>
          <group group_id="O1">
            <title>RNF 44Mcg Three Times Weekly/RNF 44Mcg Three Times Weekly(OLE)</title>
            <description>Participants who were not converted to CDMS and completed 24 month core REFLEX trial were enrolled in a 1 year open label extension (OLE). Participants who had received RNF three times a week in the core REFLEX trial, were re-titrated with a single dose of RNF injection administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 36 months in this 12 months open label extension.</description>
          </group>
          <group group_id="O2">
            <title>RNF 44 Mcg Once Weekly/RNF 44 Mcg Three Times Weekly (OLE)</title>
            <description>Participants who were not converted to CDMS and completed 24 month core REFLEX trial were enrolled in a 1 year OLE. Participants who had received RNF once weekly in the core REFLEX trial were re-titrated with a single dose of RNF injection subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 36 months in this 12 months open label extension.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/RNF 44 Mcg Three Times Weekly (OLE)</title>
            <description>Participants who were not converted to CDMS and completed 24 month core REFLEX trial were enrolled in a 1 year OLE. Participants who had received placebo in the core REFLEX trial were re-titrated with a single dose of RNF injection subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 36 months in this 12 months open label extension.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) Defined by Either a Second Attack or a 3-Month Sustained Increase (Greater Than or Equal to 1.5 Points) in the Expanded Disability Status Scale (EDSS) Score</title>
          <description>CDMS was defined by the occurrence of a second exacerbation or relapse over 36 months in participants who presented with FCDE accompanied by an abnormal MRI scan. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated.</description>
          <population>OL ITT population included all participants who were randomized at baseline in core REFLEX trial and entered the 12 months OLE period.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Insufficient participants reached the median percentile to calculate the upper and lower limits of confidence interval.</measurement>
                    <measurement group_id="O2" value="NA">Insufficient participants reached the median percentile to calculate the upper and lower limits of confidence interval.</measurement>
                    <measurement group_id="O3" value="NA">Insufficient participants reached the median percentile to calculate the upper and lower limits of confidence interval.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Combined Unique Active (CUA) Lesions, New Time Constant 2 (T2) Lesions, Gadolinium Enhanced (Gd+) Lesions and New Time Constant 1 (T1) Hypointense Lesions Per Participant Per Scan</title>
        <description>Number of CUA lesions, new T2 lesions, Gd+ lesions and new T1 hypointense lesions were measured by using MRI scans.</description>
        <time_frame>Month 24 up to Month 36</time_frame>
        <population>OL ITT population included all participants who were randomized at baseline in core REFLEX trial and entered the 12 months OLE period. &quot;n&quot; signifies those participants who were evaluated for this measure at the specified time point for each arm group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>RNF 44Mcg Three Times Weekly/RNF 44Mcg Three Times Weekly(OLE)</title>
            <description>Participants who were not converted to CDMS and completed 24 month core REFLEX trial were enrolled in a 1 year open label extension (OLE). Participants who had received RNF three times a week in the core REFLEX trial, were re-titrated with a single dose of RNF injection administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 36 months in this 12 months open label extension.</description>
          </group>
          <group group_id="O2">
            <title>RNF 44 Mcg Once Weekly/RNF 44 Mcg Three Times Weekly (OLE)</title>
            <description>Participants who were not converted to CDMS and completed 24 month core REFLEX trial were enrolled in a 1 year OLE. Participants who had received RNF once weekly in the core REFLEX trial were re-titrated with a single dose of RNF injection subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 36 months in this 12 months open label extension.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/RNF 44 Mcg Three Times Weekly (OLE)</title>
            <description>Participants who were not converted to CDMS and completed 24 month core REFLEX trial were enrolled in a 1 year OLE. Participants who had received placebo in the core REFLEX trial were re-titrated with a single dose of RNF injection subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 36 months in this 12 months open label extension.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Combined Unique Active (CUA) Lesions, New Time Constant 2 (T2) Lesions, Gadolinium Enhanced (Gd+) Lesions and New Time Constant 1 (T1) Hypointense Lesions Per Participant Per Scan</title>
          <description>Number of CUA lesions, new T2 lesions, Gd+ lesions and new T1 hypointense lesions were measured by using MRI scans.</description>
          <population>OL ITT population included all participants who were randomized at baseline in core REFLEX trial and entered the 12 months OLE period. &quot;n&quot; signifies those participants who were evaluated for this measure at the specified time point for each arm group respectively.</population>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CUA lesions (n=3,5,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="0.58"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="1.56" spread="2.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New T2 lesions (n=3,5,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.29"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.94" spread="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Gd+ lesions (n=3,5,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.29"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.56" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New T1 Hypointense lesions (n=3,5,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.29"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.56" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Time Constant 2 (T2) Lesion Volume , Time Constant 1 (T1) Hypointense Lesion Volume and Gadolinium Enhanced (Gd+) Lesion Volume at Month 36</title>
        <description>Change from baseline in lesion volume was measured by using MRI scans for T2 lesions, T1 hypointense lesions and (Gd+) lesions.</description>
        <time_frame>Baseline, Month 36</time_frame>
        <population>OL ITT population included all participants who were randomized at baseline in core REFLEX trial and entered the 12 months OLE period. &quot;n&quot; signifies those participants who were evaluated for this measure at the specified time point for each arm group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>RNF 44Mcg Three Times Weekly/RNF 44Mcg Three Times Weekly(OLE)</title>
            <description>Participants who were not converted to CDMS and completed 24 month core REFLEX trial were enrolled in a 1 year open label extension (OLE). Participants who had received RNF three times a week in the core REFLEX trial, were re-titrated with a single dose of RNF injection administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 36 months in this 12 months open label extension.</description>
          </group>
          <group group_id="O2">
            <title>RNF 44 Mcg Once Weekly/RNF 44 Mcg Three Times Weekly (OLE)</title>
            <description>Participants who were not converted to CDMS and completed 24 month core REFLEX trial were enrolled in a 1 year OLE. Participants who had received RNF once weekly in the core REFLEX trial were re-titrated with a single dose of RNF injection subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 36 months in this 12 months open label extension.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/RNF 44 Mcg Three Times Weekly (OLE)</title>
            <description>Participants who were not converted to CDMS and completed 24 month core REFLEX trial were enrolled in a 1 year OLE. Participants who had received placebo in the core REFLEX trial were re-titrated with a single dose of RNF injection subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 36 months in this 12 months open label extension.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Time Constant 2 (T2) Lesion Volume , Time Constant 1 (T1) Hypointense Lesion Volume and Gadolinium Enhanced (Gd+) Lesion Volume at Month 36</title>
          <description>Change from baseline in lesion volume was measured by using MRI scans for T2 lesions, T1 hypointense lesions and (Gd+) lesions.</description>
          <population>OL ITT population included all participants who were randomized at baseline in core REFLEX trial and entered the 12 months OLE period. &quot;n&quot; signifies those participants who were evaluated for this measure at the specified time point for each arm group respectively.</population>
          <units>cubic millimeter (mm^3)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>T2 lesion volume at Baseline (n=4,5,11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="675.20" spread="940.87"/>
                    <measurement group_id="O2" value="1703.48" spread="1324.41"/>
                    <measurement group_id="O3" value="3533.37" spread="3914.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2 lesion volume change at Month 36 (n=2,4,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180.25" spread="198.34"/>
                    <measurement group_id="O2" value="-22.63" spread="382.14"/>
                    <measurement group_id="O3" value="-1155.63" spread="3348.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1 lesion volume at Baseline (n=4,5,11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.05" spread="60.10"/>
                    <measurement group_id="O2" value="302.70" spread="358.58"/>
                    <measurement group_id="O3" value="488.72" spread="589.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1 lesion volume change at Month 36 (n=2,4,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.75" spread="78.84"/>
                    <measurement group_id="O2" value="216.68" spread="310.06"/>
                    <measurement group_id="O3" value="138.89" spread="339.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gd+ lesion volume at Baseline (n=4,5,11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.70" spread="151.17"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="287.15" spread="649.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gd+ lesion volume change at Month 36 (n=2,4,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-47.20" spread="66.75"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="-246.08" spread="848.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Conversion to Multiple Sclerosis (MS) According to the McDonald Criteria (2005)</title>
        <description>The McDonald criteria use dissemination in time and space established by MRI findings to provide a clinical diagnosis for MS. Dissemination in time is established by a T2 or Gd+ lesion found on a repeat MRI. Dissemination in space is established by the presence of any 3 of the following: 1 Gd+ lesion or 9 T2 bright lesions if there is no enhancement; greater than or equal to 1 infratentorial lesion; greater than or equal to 1 juxtacortical lesion; greater than or equal to 3 periventricular lesions.</description>
        <time_frame>Various time points from randomization up to 36 months</time_frame>
        <population>Open label (OL) ITT population included all participants who were randomized at baseline in core REFLEX trial and entered the 12 months OLE period.</population>
        <group_list>
          <group group_id="O1">
            <title>RNF 44Mcg Three Times Weekly/RNF 44Mcg Three Times Weekly(OLE)</title>
            <description>Participants who were not converted to CDMS and completed 24 month core REFLEX trial were enrolled in a 1 year open label extension (OLE). Participants who had received RNF three times a week in the core REFLEX trial, were re-titrated with a single dose of RNF injection administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 36 months in this 12 months open label extension.</description>
          </group>
          <group group_id="O2">
            <title>RNF 44 Mcg Once Weekly/RNF 44 Mcg Three Times Weekly (OLE)</title>
            <description>Participants who were not converted to CDMS and completed 24 month core REFLEX trial were enrolled in a 1 year OLE. Participants who had received RNF once weekly in the core REFLEX trial were re-titrated with a single dose of RNF injection subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 36 months in this 12 months open label extension.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/RNF 44 Mcg Three Times Weekly (OLE)</title>
            <description>Participants who were not converted to CDMS and completed 24 month core REFLEX trial were enrolled in a 1 year OLE. Participants who had received placebo in the core REFLEX trial were re-titrated with a single dose of RNF injection subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 36 months in this 12 months open label extension.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Conversion to Multiple Sclerosis (MS) According to the McDonald Criteria (2005)</title>
          <description>The McDonald criteria use dissemination in time and space established by MRI findings to provide a clinical diagnosis for MS. Dissemination in time is established by a T2 or Gd+ lesion found on a repeat MRI. Dissemination in space is established by the presence of any 3 of the following: 1 Gd+ lesion or 9 T2 bright lesions if there is no enhancement; greater than or equal to 1 infratentorial lesion; greater than or equal to 1 juxtacortical lesion; greater than or equal to 3 periventricular lesions.</description>
          <population>Open label (OL) ITT population included all participants who were randomized at baseline in core REFLEX trial and entered the 12 months OLE period.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data could not be analyzed as none of the participants converted to MS according to the McDonald Criteria in the 12 month OLE period.</measurement>
                    <measurement group_id="O2" value="NA">Data could not be analyzed as none of the participants converted to MS according to the McDonald Criteria in the 12 month OLE period.</measurement>
                    <measurement group_id="O3" value="NA">Data could not be analyzed as none of the participants converted to MS according to the McDonald Criteria in the 12 month OLE period.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Expanded Disability Status Score (EDSS) Score at Month 36</title>
        <description>EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. The change in EDSS at Month 36 was calculated as EDSS at Month 36 minus EDSS at baseline.</description>
        <time_frame>Baseline, Month 36</time_frame>
        <population>OL ITT population included all participants who were randomized at baseline in core REFLEX trial and entered the 12 months OLE period. &quot;n&quot; signifies those participants who were evaluated for this measure at the specified time point for each arm group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>RNF 44Mcg Three Times Weekly/RNF 44Mcg Three Times Weekly(OLE)</title>
            <description>Participants who were not converted to CDMS and completed 24 month core REFLEX trial were enrolled in a 1 year open label extension (OLE). Participants who had received RNF three times a week in the core REFLEX trial, were re-titrated with a single dose of RNF injection administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 36 months in this 12 months open label extension.</description>
          </group>
          <group group_id="O2">
            <title>RNF 44 Mcg Once Weekly/RNF 44 Mcg Three Times Weekly (OLE)</title>
            <description>Participants who were not converted to CDMS and completed 24 month core REFLEX trial were enrolled in a 1 year OLE. Participants who had received RNF once weekly in the core REFLEX trial were re-titrated with a single dose of RNF injection subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 36 months in this 12 months open label extension.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/RNF 44 Mcg Three Times Weekly (OLE)</title>
            <description>Participants who were not converted to CDMS and completed 24 month core REFLEX trial were enrolled in a 1 year OLE. Participants who had received placebo in the core REFLEX trial were re-titrated with a single dose of RNF injection subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 36 months in this 12 months open label extension.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Expanded Disability Status Score (EDSS) Score at Month 36</title>
          <description>EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. The change in EDSS at Month 36 was calculated as EDSS at Month 36 minus EDSS at baseline.</description>
          <population>OL ITT population included all participants who were randomized at baseline in core REFLEX trial and entered the 12 months OLE period. &quot;n&quot; signifies those participants who were evaluated for this measure at the specified time point for each arm group respectively.</population>
          <units>unit on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=4,5,11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.88" spread="0.85"/>
                    <measurement group_id="O2" value="1.60" spread="0.96"/>
                    <measurement group_id="O3" value="1.64" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 36 (n=2,4,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" spread="1.06"/>
                    <measurement group_id="O2" value="-0.63" spread="0.48"/>
                    <measurement group_id="O3" value="-0.50" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>An adverse event (AE) was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an Investigational Medicinal Product (IMP), regardless of causal relationship and even if no IMP has been administered.</desc>
      <group_list>
        <group group_id="E1">
          <title>RNF 44 Mcg Three Times Weekly (Double Blind [DB] Population)</title>
          <description>Single dose of fetal bovine serum [FBS]-free/human serum albumin [HSA]-free formulation of interferon [IFN]-beta-1a (RNF) injection administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 microgram (mcg) for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months or until conversion to CDMS whichever occurs first.</description>
        </group>
        <group group_id="E2">
          <title>RNF 44 Mcg Once Weekly (DB Population)</title>
          <description>Single dose of RNF injection administered subcutaneously once weekly plus 2 matching placebo doses at least 48 hours apart at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months or until conversion to CDMS whichever occurs first.</description>
        </group>
        <group group_id="E3">
          <title>Placebo (DB Population)</title>
          <description>Single dose of matching placebo administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months or until conversion to CDMS whichever occurs first.</description>
        </group>
        <group group_id="E4">
          <title>RNF 44 Mcg Three Times Weekly/OL RNF 44 Mcg Three Times Weekly</title>
          <description>After having converted to CDMS, participants received open-label (OL) study treatment with RNF. Single dose of RNF injection administrated subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months.</description>
        </group>
        <group group_id="E5">
          <title>RNF 44 Mcg Once Weekly/OL RNF 44 Mcg Three Times Weekly</title>
          <description>After having converted to CDMS, participants received OL study treatment with RNF. Single dose of RNF injection administrated subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months.</description>
        </group>
        <group group_id="E6">
          <title>Placebo/OL RNF 44 Mcg Three Times Weekly</title>
          <description>After having converted to CDMS, participants received OL study treatment with RNF. Single dose of RNF injection administrated subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months.</description>
        </group>
        <group group_id="E7">
          <title>RNF 44Mcg Three Times Weekly/RNF 44Mcg Three Times Weekly(OLE)</title>
          <description>Participants who were not converted to CDMS and completed 24 month core REFLEX trial were enrolled in a 1 year open label extension (OLE). Participants who had received RNF three times a week in the core REFLEX trial, were re-titrated with a single dose of RNF injection administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 36 months in this 12 months open label extension.</description>
        </group>
        <group group_id="E8">
          <title>RNF 44 Mcg Once Weekly/RNF 44 Mcg Three Times Weekly (OLE)</title>
          <description>Participants who were not converted to CDMS and completed 24 month core REFLEX trial were enrolled in a 1 year OLE. Participants who had received RNF once weekly in the core REFLEX trial were re-titrated with a single dose of RNF injection subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 36 months in this 12 months open label extension.</description>
        </group>
        <group group_id="E9">
          <title>Placebo/RNF 44 Mcg Three Times Weekly (OLE)</title>
          <description>Participants who were not converted to CDMS and completed 24 month core REFLEX trial were enrolled in a 1 year OLE. Participants who had received placebo in the core REFLEX trial were re-titrated with a single dose of RNF injection subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 36 months in this 12 months open label extension.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="171"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness congenital</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dermoid cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal motility disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pancreatic necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="171"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Post procedural hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer stage III</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Ovarian germ cell teratoma benign</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Testis cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ischemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="171"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Cervical polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Tonsillar disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="149" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="156" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="133" subjects_at_risk="171"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="47" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="171"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="173"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E6" events="5" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E6" events="4" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="171"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="173"/>
                <counts group_id="E3" events="9" subjects_affected="6" subjects_at_risk="171"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="171"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="173"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="171"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="4" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="218" subjects_affected="93" subjects_at_risk="171"/>
                <counts group_id="E2" events="374" subjects_affected="122" subjects_at_risk="173"/>
                <counts group_id="E3" events="50" subjects_affected="34" subjects_at_risk="171"/>
                <counts group_id="E4" events="9" subjects_affected="8" subjects_at_risk="31"/>
                <counts group_id="E5" events="6" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E6" events="31" subjects_affected="24" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="76" subjects_affected="50" subjects_at_risk="171"/>
                <counts group_id="E2" events="49" subjects_affected="34" subjects_at_risk="173"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="171"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E5" events="5" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E6" events="13" subjects_affected="13" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="6" subjects_at_risk="171"/>
                <counts group_id="E2" events="29" subjects_affected="22" subjects_at_risk="173"/>
                <counts group_id="E3" events="12" subjects_affected="9" subjects_at_risk="171"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E6" events="4" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="25" subjects_affected="13" subjects_at_risk="171"/>
                <counts group_id="E2" events="12" subjects_affected="5" subjects_at_risk="173"/>
                <counts group_id="E3" events="26" subjects_affected="11" subjects_at_risk="171"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="26" subjects_affected="11" subjects_at_risk="171"/>
                <counts group_id="E2" events="27" subjects_affected="9" subjects_at_risk="173"/>
                <counts group_id="E3" events="11" subjects_affected="5" subjects_at_risk="171"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="4" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="171"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="173"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="171"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="21" subjects_affected="17" subjects_at_risk="171"/>
                <counts group_id="E2" events="30" subjects_affected="23" subjects_at_risk="173"/>
                <counts group_id="E3" events="49" subjects_affected="22" subjects_at_risk="171"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="37" subjects_affected="17" subjects_at_risk="171"/>
                <counts group_id="E2" events="19" subjects_affected="13" subjects_at_risk="173"/>
                <counts group_id="E3" events="34" subjects_affected="20" subjects_at_risk="171"/>
                <counts group_id="E4" events="6" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="171"/>
                <counts group_id="E2" events="17" subjects_affected="10" subjects_at_risk="173"/>
                <counts group_id="E3" events="20" subjects_affected="17" subjects_at_risk="171"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="171"/>
                <counts group_id="E2" events="9" subjects_affected="5" subjects_at_risk="173"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="171"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="19" subjects_affected="9" subjects_at_risk="171"/>
                <counts group_id="E2" events="12" subjects_affected="6" subjects_at_risk="173"/>
                <counts group_id="E3" events="18" subjects_affected="8" subjects_at_risk="171"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" events="7" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E6" events="4" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="171"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="173"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="171"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="171"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="173"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="171"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Anti-thyroid antibody positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="12" subjects_at_risk="171"/>
                <counts group_id="E2" events="17" subjects_affected="11" subjects_at_risk="173"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="171"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="6" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="145" subjects_affected="46" subjects_at_risk="171"/>
                <counts group_id="E2" events="129" subjects_affected="37" subjects_at_risk="173"/>
                <counts group_id="E3" events="135" subjects_affected="46" subjects_at_risk="171"/>
                <counts group_id="E4" events="20" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E6" events="14" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="7" subjects_at_risk="171"/>
                <counts group_id="E2" events="17" subjects_affected="8" subjects_at_risk="173"/>
                <counts group_id="E3" events="27" subjects_affected="16" subjects_at_risk="171"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="171"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="173"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="171"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="171"/>
                <counts group_id="E2" events="21" subjects_affected="7" subjects_at_risk="173"/>
                <counts group_id="E3" events="20" subjects_affected="14" subjects_at_risk="171"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vulvovaginal pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="171"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="173"/>
                <counts group_id="E3" events="14" subjects_affected="11" subjects_at_risk="171"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor has the right to publish any results communication in connection with the study. The PI shall submit any communications including study results to the sponsor for review 30 working days prior to communication submission. The sponsor can request the PI to modify or delete any sponsor's proprietary information. If the PI refuses the modification, the submission shall be postponed for 60 days from PI refusal, to provide the sponsor the opportunity to file a patent or seek legal remedies.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Merck KGaA Communication Center</name_or_title>
      <organization>Merck Serono, a division of Merck KGaA</organization>
      <phone>+49-6151-72-5200</phone>
      <email>service@merckgroup.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

